|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Western blot revealed enhanced expression of CD133 in exosomes obtained from patients with pancreatic cancer compared to those obtained from patients with gastric cancer or liver cirrhosis.
|
30805710 |
2019 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Univariate and multivariate Cox proportional hazards analysis revealed that tumor stage, CD133 expression, vascular invasion and sex were independent predictors of disease-free survival (DFS) time, and tumor size, vascular invasion and sex were independent predictors of overall survival (OS) time in patients with GC.
|
31611965 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The CD133+ GC stem-like cells were sorted by flow cytometry, after which immunofluorescence assay was used to determine the co-localization of CD133 and CD44v8-10.
|
31438772 |
2019 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Several gastric stem cell (GSC) markers including CD44, CD133, and Lgr5 are upregulated in GC.
|
29084052 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133 Expression as a <i>Helicobacter pylori</i>-independent Biomarker of Gastric Cancer Progression.
|
30061208 |
2018 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluation of METase-pemetrexed-loaded PEG-PLGA nanoparticles modified with anti-CD133-scFV for treatment of gastric carcinoma.
|
29229675 |
2018 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate whether CD133 is involved in the TGF-β1-induced activation of the ERK/P70S6K signaling pathway in GC cells, immunomagnetic cell sorting was employed to isolate CD133<sup>+</sup> GC cells, and a CD133-expression construct or CD133-targeting small interfering ribonucleic acids were transfected into cells to modulate the expression of CD133.
|
29344155 |
2017 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133 polymorphisms are promising biomarkers for genetic susceptibility and prognosis prediction of gastric cancer.
|
28326835 |
2017 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Low expressions of Oct4-EpCAM in IHC and CD133 in qPCR were favorable prognostic factors in GC.
|
27557490 |
2016 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Similarly, only poorly-differentiated gastric cancer cell lines expressed CD133 and activated-Notch1.
|
27489358 |
2016 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The roles of serum PDCD5 in circulating CD133 positive cells of the patients with gastric cancer.
|
27034262 |
2016 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The relationship of CD133, histone deacetylase 1 and thrombospondin-1 in gastric cancer.
|
25862862 |
2015 |
|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that these two CD133 miRNA binding site variants, rs2240688 and rs3130, may be potential biomarkers for genetic susceptibility to GC and possible predictors for survival in GC patients but require further validation by larger studies.
|
24302553 |
2015 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We isolated CD133+ GC cells by immunomagnetic cell sorting and CD133 expression was modulated by transfection of CD133 gene or CD133 small interfering ribonucleic acid.
|
25230779 |
2014 |
|
Stomach Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Demethylation of the CD133 gene is frequently detected in early gastric carcinoma.
|
20530428 |
2010 |